Insmed Incorporated Insmed Incorporated

Insmed Incorporated

INSM

Classifica tra le azioni #1105
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Prezzo delle azioni
$96.95
Capitalizzazione di mercato
$21.17B
Variazione (1 giorno)
1.74%
Variazione (1 anno)
-42.26%
Paese
US
Scambia Insmed Incorporated (INSM)

Categoria

Healthcare
Cronologia dei frazionamenti azionari per Insmed Incorporated (INSM)
L’azione Insmed Incorporated (simbolo: INSM) ha subito un totale di 2 frazionamenti.
L’ultimo frazionamento è avvenuto il Mar 03, 2011.
Una quota di INSM acquistata prima di Jul 31, 2000 equivale oggi a 0.025 quote di INSM.
Elenco dei frazionamenti azionari
Anno Frazionamento Moltiplicatore Moltiplicatore cumulativo
2011-03-03 1:10 x0.1 x0.025
2000-07-31 1:4 x0.25 x0.25
Frazionamenti azionari di aziende simili o concorrenti
Azienda Numero di frazionamenti azionari Moltiplicatore cumulativo Il paese
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL